Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Candesartan (CV 11974) 是一种血管紧张素II 受体拮抗剂(IC50:0.26 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 176 | 现货 | ||
5 mg | ¥ 315 | 现货 | ||
10 mg | ¥ 492 | 现货 | ||
25 mg | ¥ 977 | 现货 | ||
50 mg | ¥ 1,650 | 现货 | ||
100 mg | ¥ 2,490 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 397 | 现货 |
产品描述 | Candesartan (CV 11974) is an angiotensin II receptor blocker used widely in the therapy of hypertension and heart failure. |
靶点活性 | AT1 receptor:0.26 nM |
体外活性 | 在处理携带KU-19-19移植瘤的小鼠中,Candesartan(10 mg/kg)能够降低微血管密度和VEGF的表达,抑制肿瘤细胞生长.在WKY大鼠中,Candesartan(0.5 mg/kg )能够降低血压,抑制AT1在穹窿下器,下丘脑室旁核,孤束核,和极后区的结合.在成年自发性高血压大鼠中,Candesartan(0.3 mg/kg)能够减少梗死区域,减少在缺血周边区域和皮层下严重缺血性病变区域,减低脑部血流量的减少. |
体内活性 | 在CHO-AT1细胞中,Candesartan 能够高选择性地与血管紧张素II AT1 受体结合。Candesartan(0.1 nM)能够降低对于血管紧张素II的最大收缩反应。在 KU-19-19细胞中,加入Candesartan,能够上调VEGF和和白细胞介素-8的表达,同时不影响细胞增殖。 |
激酶实验 | Binding assay: Cells are plated in 24-well plates and cultured until confluence. Before the experiment, the cells are washed three times with 0.5 mL per well of DMEM at room temperature. After removal of the medium, 400 μL binding DMEM is added and the plate is then left for 15 min at 37 ℃. For saturation binding assays cells are incubated with increasing concentrations [3H]Candesartan (final concentrations between 0.15 nM and 15 nM) in a final volume of 0.5 mL at 37 ℃ for 5 min to 180 min. For competition binding assays 50 μL of buffer or 50 μL of buffer containing increasing concentrations of unlabelled Candesartan is added. After 30 min, 50 μL of buffer containing [3H]Candesartan (final concentration 1.1 nM) or [3H]Candesartan (final concentration 1.0 nM) is added, and the cells are further incubated for 30 min at 37 ℃. |
细胞实验 | KU-19-19 cells are seeded at a cell density of 2 × 104 per well in 96-well plates and allowed to grow overnight. Then the cells are treated with various concentrations of Candesartan for various periods of time. Cell viability is determined by the Alamar Blue assay to examine the cytotoxicity and antiproliferative effect of candesartan. The absorbance value of each well is determined in a microplate reade(Only for Reference) |
别名 | CV 11974, 坎地沙坦 |
分子量 | 440.47 |
分子式 | C24H20N6O3 |
CAS No. | 139481-59-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.5 mg/mL (100 mM)
Ethanol: 0.4 mg/mL (10 mM)), with gentle warming
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.2703 mL | 11.3515 mL | 22.703 mL | 56.7576 mL |
5 mM | 0.4541 mL | 2.2703 mL | 4.5406 mL | 11.3515 mL | |
10 mM | 0.227 mL | 1.1352 mL | 2.2703 mL | 5.6758 mL | |
DMSO | 20 mM | 0.1135 mL | 0.5676 mL | 1.1352 mL | 2.8379 mL |
50 mM | 0.0454 mL | 0.227 mL | 0.4541 mL | 1.1352 mL | |
100 mM | 0.0227 mL | 0.1135 mL | 0.227 mL | 0.5676 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Candesartan 139481-59-7 Endocrinology/Hormones RAAS inhibit CV 11974 angiotensin II AT1-Receptor hypertension hronic heart failure (CHF) antihypertensive oral CV-11974 Angiotensin Receptor Traumatic brain injury (TBI) PPAR-γ CV11974 Inhibitor 坎地沙坦 inhibitor